Thursday, Jun 30, 2022
English News
  • Hyderabad
  • Telangana
  • Andhra Pradesh
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Reviews
    • Education Today
    • Property
    • Videos
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
Home | Business | Sun Pharma To Launch Complete Range Of Generic Anti Epilepsy Drug
Ads

Sun Pharma to launch complete range of generic anti-epilepsy drug

By PTI
Published: Published Date - 04:19 PM, Tue - 23 February 21
Representational Image. Sun Pharma plans to introduce a complete range of anti-epilepsy drug Brivaracetam in the country at an affordable price.

New Delhi: Sun Pharmaceutical Industries on Tuesday said it plans to introduce a complete range of anti-epilepsy drug Brivaracetam in the country at an affordable price.

The drug major introduced Brevipil (Brivaracetam) tablet in strengths of 25 mg/50 mg/75 mg/100 mg on February 21, while Brevipil oral solution (10 mg/ml) and injectable (10 mg/ml) will be available in the market over the next few weeks.

Brivaracetam is approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.

“We are introducing the complete range of Brivaracetam in India at a competitive pricing which will improve patient access. This product reaffirms our commitment towards improving epilepsy care by bringing multiple treatment options to patients and health care professionals in India,” Sun Pharma Chief Executive Officer – India Business Kirti Ganorkar said in a statement.

Brivaracetam belongs to the class of anti-epileptic drugs (AEDs) which have a unique or different mechanism of action compared to the existing treatment options. It has fast onset of action and promising efficacy.

While epilepsy is a common neurological disorder, because of the social stigma surrounding the disease, cultural practices and poor awareness of new treatment options, its management continues to be a challenge, the drug major said.

It is estimated that around 5.7 million to 6.4 million people in India suffer from epilepsy, it added.

  • Follow Us :
  • Tags
  • anti-epilepsy drug
  • Brivaracetam
  • generic
  • Sun Pharma

Related News

  • Pharma industry optimistic about 2022-23 horizon

  • Dr Chandak of CCMB selected for Sun Pharma Science Foundation Research award

  • Covid antiviral drug Molnupiravir launched in India

  • Sun Pharma settles patent dispute with US Celgene Corporation

  • No plans to get into vaccine production: Sun Pharma

  • MSN Laboratories launches Favipiravir 800mg tablets

Latest News

  • CM KCR nominates heads for three State-level organisations

    14 mins ago
  • Hyderabad: Malladi Brothers enthral listeners at SICA event

    17 mins ago
  • Hyderabad well suited for Global Capability Centres: KT Rama Rao

    6 mins ago
  • Telangana: BIE issues schedule for inter first year admissions

    42 mins ago
  • UPSC IFS results: Rachakonda CP helps 50 aspirants in cracking interview

    48 mins ago
  • Telangana POLYCET 2022 results likely on July 13 or 14

    60 mins ago
  • No major rainfall on forecast in Hyderabad

    1 hour ago
  • ‘Ji Huzoor’ is rare break-free moment Kaza prisoners experience: Ranbir Kapoor

    1 hour ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam